Brands: Apriso · Mesalamine
Average across 10 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Alembic Pharmaceuticals Limited | generic | 4 | SUPPLYING |
| Ascend Laboratories, LLC | generic | 2 | SUPPLYING |
| Sandoz Inc | generic | 2 | SUPPLYING |
| Salix Pharmaceuticals, Inc. | unknown | 2 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | generic | 1 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | generic | 1 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 1 | SUPPLYING |
| Camber Pharmaceuticals, Inc. | generic | 1 | SUPPLYING |
| AvPAK | repackager | 1 | SUPPLYING |
| Ingenus Pharmaceuticals, LLC | unknown | 1 | SUPPLYING |
| American Health Packaging | repackager | 1 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | generic | 1 | SUPPLYING |
| Oceanside Pharmaceuticals | unknown | 1 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 1 | SUPPLYING |
| Aurobindo Pharma Limited | generic | 1 | SUPPLYING |
+ 2 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
Mesalamine Capsule, Extended Release — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Gastroenterology.
Mesalamine Capsule, Extended Release — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Gastroenterology.
Failed Dissolution Specifications: Out of specification for dissolution. — Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC — Nationwide in the U.S.
